Who
Marvin L. White
Executive Chair
Company insider
Files Form 4 as: Executive Chair, Aptevo Therapeutics; Director, Emergent BioSolutions; Director, CoLucid Pharmaceuticals; Director, WP Glimcher.
In numbers
- Trades disclosed
- 121
- Buys
- 7
- Sells
- 3
- Bought
- $464K
- Sold
- $1.6M
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 1 Jun 2010
- Last trade
- 6 Aug 2026
- Last filed
- 10 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Aug 2026filed 10 Aug 2026 | APVO Aptevo TherapeuticsBiotechnology | SEC FORM 4 Code M | —1,666 | filing |
| 6 Aug 2026filed 10 Aug 2026 | APVO Aptevo TherapeuticsBiotechnology | SEC FORM 4 Code F | $1,652406 at $4.07 | filing |
| 6 Aug 2026filed 10 Aug 2026 | APVO Aptevo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,666 at $0.00 | filing |
| 6 Aug 2026filed 10 Aug 2026 | APVO Aptevo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,666 at $0.00 | filing |
| 6 Aug 2026filed 10 Aug 2026 | APVO Aptevo TherapeuticsBiotechnology | SEC FORM 4 Code M | —1,666 | filing |
| 6 Aug 2026filed 10 Aug 2026 | APVO Aptevo TherapeuticsBiotechnology | SEC FORM 4 Code F | $1,652406 at $4.07 | filing |
| 17 Jul 2026filed 10 Aug 2026 | APVO Aptevo TherapeuticsBiotechnology | SEC FORM 4 Code M | —1 | filing |
| 17 Jul 2026filed 10 Aug 2026 | APVO Aptevo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1 at $0.00 | filing |
| 17 Jul 2026filed 10 Aug 2026 | APVO Aptevo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1 at $0.00 | filing |
| 17 Jul 2026filed 10 Aug 2026 | APVO Aptevo TherapeuticsBiotechnology | SEC FORM 4 Code M | —1 | filing |
| 30 Apr 2026filed 4 May 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —25,344 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,296 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,296 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —25,344 at $0.00 | filing |
| 6 Aug 2025filed 8 Aug 2025 | APVO Aptevo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 17 Jul 2025filed 21 Jul 2025 | APVO Aptevo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10 at $0.00 | filing |
| 17 Jul 2025filed 21 Jul 2025 | APVO Aptevo TherapeuticsBiotechnology | SEC FORM 4 Code M | —10 | filing |
| 30 Apr 2025filed 2 May 2025 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,824 at $0.00 | filing |
| 30 Apr 2025filed 2 May 2025 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —34,403 at $0.00 | filing |
| 3 Mar 2025filed 4 Mar 2025 | APVO Aptevo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6 at $0.00 | filing |
News
Comparing Monte Rosa Therapeutics (NASDAQ:GLUE) and Emergent Biosolutions (NYSE:EBS)EBS · tickerreport.com · 16 Oct 2026Aptevo Therapeutics: Aptevo to Showcase Multispecific Platform at SITC 2026 Annual MeetingAPVO · finanznachrichten.de · 14 Oct 2026
0 headlines in the last 90 days name Marvin L. White; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.